MedPath
FDA Approval

Ibandronate Sodium

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Accord Healthcare Inc.
DUNS: 604222237
Effective Date
January 9, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ibandronate(3 mg in 3 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Intas Pharmaceuticals Limited.

Accord Healthcare Inc.

725927649

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ibandronate Sodium

Product Details

NDC Product Code
16729-274
Application Number
ANDA206058
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
January 9, 2024
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACT
Code: J12U072QL0Class: ACTIMQuantity: 3 mg in 3 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACT
© Copyright 2025. All Rights Reserved by MedPath